In our previous article, over 45 different nonapproved nanoparticles (liposomes, polymeric, micelles, albumin‐bound nanoparticles, and inorganic nanoparticles) were listed as active in a total of over 80 different clinical trials (mostly for the treatment of various cancers but also radiation exposure, arthritis, pneumonia, amyloidosis, hepatitis, and fibrosis). This evidence concerns the gene ALB and cancer.